Phase 1 × Recruiting × Kidney Neoplasms × Clear all
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
NCT06673329 2025-05-14

Brodalumab in the Treatment of Immune-Related Adverse Events

Columbia University

Phase 1 Recruiting
11 enrolled